Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the European Medicines Agency (EMA) has accepted for
review a Marketing Authorization Application (MAA) for pembrolizumab
(MK-3475), the company’s investigational anti-PD-1 antibody, for the
treatment of advanced melanoma. If approved by the European Commission
(EC), pembrolizumab has the potential to be the first anti-PD-1 therapy
in Europe.
Language:
English
Contact:
Media:Steve Cragle, 973-432-4781Claire Mulhear, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Source Type: news
More News: Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Melanoma | Merck | Pharmaceuticals | Skin Cancer